Welcome to Conversations in Lung Cancer Research, presented by TOGA, your go-to podcast for in-depth insights into lung cancer. Tune in for conversations with leading experts, inspiring stories, and the latest updates on clinical trials. Stay informed and empowered in the fight against lung cancer.
All content for Conversations in Lung Cancer Research is the property of Thoracic Oncology Group Of Australasia (TOGA) and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Welcome to Conversations in Lung Cancer Research, presented by TOGA, your go-to podcast for in-depth insights into lung cancer. Tune in for conversations with leading experts, inspiring stories, and the latest updates on clinical trials. Stay informed and empowered in the fight against lung cancer.
In this episode of Conversations in Lung Cancer Research, A/Prof Mel Moore, along with thoracic oncologists Dr. Malinda Itchins and A/Prof Surein Arulananda, delve into the characteristics, detection, and treatment of EGFR exon 20 insertion mutant non-small cell lung cancer. The podcast discusses recent advances, the efficacy of various treatments including small molecule tyrosine kinase inhibitors and monoclonal antibodies, and the potential future of targeted therapies. Special focus is given to the Phase 3 Papillon study and the drug Amivantamab, highlighting the need for next generation sequencing in clinical settings. Key challenges and questions in the field are also addressed, including the impact of co-mutations and optimal therapy sequencing.
Conversations in Lung Cancer Research
Welcome to Conversations in Lung Cancer Research, presented by TOGA, your go-to podcast for in-depth insights into lung cancer. Tune in for conversations with leading experts, inspiring stories, and the latest updates on clinical trials. Stay informed and empowered in the fight against lung cancer.
